Tüdőrák: vizsgálatok itt: Kína

In Kína 1144 Also abroad 2746

1144 trials · From ClinicalTrials.gov, checked 2026. november 15.. Ask the study team whether a trial fits you.

2/3. fázisTaking people
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Where
Beijing, Chengdu, Fuzhou, Guangzhou, Nanchang, Shanghai, Wuhan
Életkor
18 év and over
People
854 worldwide
Run by
AbbVie
See details and how to joinNCT07005102
2/3. fázisTaking people
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Where
Guangzhou, Nanchang, Shanghai, Ürümqi
Életkor
18 év and over
People
490 worldwide
Run by
AbbVie
See details and how to joinNCT07155187 · EU 2025-521124-29-00
2. fázisTaking people
Multicenter, Single-Arm, Prospective Phase II Study of Neoadjuvant Cryo-Thermal Ablation Combined With Toripalimab and Chemotherapy for Resectable Stage IB-IIIB Non-Small Cell Lung Cancer
Where
Chengdu, Luzhou, Meishan, Nanchong, Suining, Zigong
Életkor
18 év to 80 év
People
40
Run by
West China Hospital
See details and how to joinNCT07855965
2. fázisTaking people
A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)
Where
Beijing
Életkor
18 év and over
People
243 worldwide
Run by
Shanghai Henlius Biotech
See details and how to joinNCT06907615 · EU 2025-523803-31-00
1/2. fázisTaking people
A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
Where
Guangzhou, Kunming
Életkor
18 év and over
People
140 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07286149 · EU 2024-512248-47-00
No phaseNot yet taking people in Kína
Video-guided Versus Conventional Right-sided Double-lumen Tube Placement for Thoracoscopic Surgery
Where
Hangzhou, Jiaxing
Életkor
18 év and over
People
566
Run by
Diansan Su
See details and how to joinNCT07849400
No phaseNot yet taking people in Kína
An Exploratory Clinical Study Of Bempemab Combined With Anlotinib As First-Line Treatment For Elderly Patients With Locally Advanced Or Metastatic Non-Small-Cell Lung Cancer
Where
Hangzhou
Életkor
75 nap and over
People
30
Run by
Zhejiang Cancer Hospital
See details and how to joinNCT07849712
2. fázisNot yet taking people in Kína
Quad Shot Radiotherapy Combined With Tislelizumab and Platinum-Based Chemotherapy Before Surgery for Stage II-III Non-Small Cell Lung Cancer
Where
Wuhan
Életkor
18 év to 75 év
People
12
Run by
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT07845916
2. fázisTaking people
Clinical Investigator-Initiated Trial (IIT) of PD-L1-Targeted Radionuclide Probes
Where
Beijing
Életkor
18 év and over
People
50
Run by
Peking University Cancer Hospital & Institute
See details and how to joinNCT07848243
No phaseTaking people
The Application of 18F-G1 PET/CT Targeting Granzyme B in the Pan-cancer Immunotherapy
Where
Beijing
Életkor
18 év to 75 év
People
120
Run by
Peking University First Hospital
See details and how to joinNCT07039474
3. fázisTaking people
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Where
Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haerbin, Hangzhou, Hefei, Jiamusi, Jinan, Langfang, Lanzhou, Linyi, Liuzhou, Nanchang, Nanjing, Nanning, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Suzhou, Taiyuan, Wuhan, Xuzhou, Yantai, Zhengzhou
Életkor
18 év and over
People
830 worldwide
Run by
AstraZeneca
See details and how to joinNCT06868277 · EU 2024-517780-24-00
2. fázisTaking people
A Prospective, Multicenter, Randomized Controlled Study on the Efficacy and Safety of Low-dose Carboplatin Combined With Nab-Paclitaxel and Delayed Administration of Serplulimab as First-line Treatment for Advanced Squamous Non-small Cell Lung Cancer
Where
Quzhou
Életkor
18 év to 75 év
People
112
Run by
People's Hospital of Quzhou
See details and how to joinNCT07647094
1. fázisNot yet taking people in Kína
A Study to Learn About the Study Medicine Called Ponsegromab in Adults With Lung Cancer-Associated Significant Body Weight Loss
Where
Shenzhen
Életkor
18 év and over
People
80 worldwide
Run by
Pfizer
See details and how to joinNCT07663630 · EU 2026-526002-32-00
No phaseTaking people
Cardiorespiratory Fitness After Lobectomy Versus Sublobar Resection
Where
Wuhan
Életkor
18 év and over
People
604
Run by
Tongji Hospital
See details and how to joinNCT07841249
2. fázisNot yet taking people in Kína
Local Consolidative Therapy Versus Maintenance Immunotherapy After First-Line Chemoimmunotherapy in Metastatic NSCLC
Where
Guangzhou
Életkor
18 év and over
People
117
Run by
Guangdong Provincial People's Hospital
See details and how to joinNCT07842471
1. fázisNot yet taking people in Kína
Phase 1 Study of ATRA Plus a PD-1 Inhibitor in EGFR-Mutant NSCLC After Third-Generation EGFR-TKI Resistance
Where
Beijing
Életkor
18 év and over
People
24
Run by
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT07842887
1/2. fázisTaking people
A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer.
Where
Guangzhou
Életkor
18 év to 75 év
People
200
Run by
Hangzhou DAC Biotechnology Co., Ltd.
See details and how to joinNCT07559929
3. fázisNot yet taking people in Kína
A Phase 3 Study of Sosimerasib in Combination With IN10018 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation
Where
Nanchang
Életkor
18 év to 75 év
People
416
Run by
Shanghai Jeyou Pharmaceutical Co., Ltd.
See details and how to joinNCT07833202
1. fázisTaking people
A Study of DXC014 in Patients With Advanced Solid Tumors.
Where
Beijing, Changsha, Hangzhou, Nanchang, Qingdao
Életkor
18 év and over
People
150
Run by
Hangzhou DAC Biotechnology Co., Ltd.
See details and how to joinNCT07177937
No phaseTaking people
Adjuvant EGFR-TKI Therapy After Surgery for EGFR-Mutant High-Risk Stage IA2-IIB NSCLC
Where
Wuhan
Életkor
18 év to 75 év
People
100
Run by
Tongji Hospital
See details and how to joinNCT07837739
1/2. fázisNot yet taking people in Kína
A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation
Where
Shanghai
Életkor
18 év to 80 év
People
26
Run by
RemeGen Co., Ltd.
See details and how to joinNCT05745740
1. fázisTaking people
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)
Where
Guangzhou, Shanghai
Életkor
18 év and over
People
232 worldwide
Run by
AbbVie
See details and how to joinNCT06858813 · EU 2024-518012-39-00
2. fázisTaking people
Low-dose Thoracic Radiotherapy Followed by Adebrelimab Plus Chemotherapy, and Then Sequential Maintenance Therapy With Adebrelimab for Extensive-stage Small Cell Lung Cancer
Where
Jiangmen
Életkor
18 év to 75 év
People
43
Run by
Jiangmen Central Hospital
See details and how to joinNCT07583550
No phaseNot yet taking people in Kína
AI-Assisted Chest CT Interpretation Across the Lung Cancer Care Continuum
Where
Wuhan
Életkor
18 év and over
People
15
Run by
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT07829640
3. fázisNot yet taking people in Kína
A Study of 7MW3711 Compared With Docetaxel in Advanced Squamous NSCLC After Prior Chemoimmunotherapy
Where
Shanghai
Életkor
18 év to 85 év
People
600
Run by
Mabwell (Shanghai) Bioscience Co., Ltd.
See details and how to joinNCT07831863